Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Strong Growth in Key Segments and .
Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical Devices, and Emerging Markets. Related Stocks: ABT
Read the full articleYou might also wanna read
Abbott Laboratories NYSE:ABT Rises on In-Line Q2 and Raised Guidance
Abbott Labs Q2 2026 earnings met expectations, slightly beating EPS estimates. The company raised its full-year guidance, boosting investor
Dividend Powerhouse: Abbott Laboratories (NYSE:ABT) Passes the Test for Sustainable Income
Abbott Laboratories offers a reliable 2.64% dividend yield backed by strong profitability, a 10-year growth history, and a reasonable P/E ra
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact
Abbott raises 2026 profit forecast on strength in diagnostics, heart devices
Abbott’s quarterly sales in its medical devices segment grew 9% to US$5.85 billion
Abbott Q2 Sales Rise 13 Percent, Boosted by Exact Sciences Acquisition
The newly created Cancer Diagnostics segment, formed following its March acquisition of Exact Sciences, posted $919 million in second-quarte
Health stocks today: Abbott (NYSE: ABT) jumps 11% as insurers split
NEW YORK, July 16, 2026, 14:23 (EDT). U.S. markets open. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) rose 2.2% to $161.81. The S
Comments
Sign in to join the conversation.
No comments yet. Be the first.